MedTrace Logo

Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction

NCT02087397 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-11-24

No results posted yet for this study

Summary

This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction cells (AD-SVF) implantation delivered into the corpus cavernous in patients with Erectile Dysfunction.

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed Erectile Dysfunction.

Conditions

Interventions

OTHER

Liposuction

Liposuction using aspiration syringe and tumescent local anesthesia

BIOLOGICAL

AD-SVF Cell Injection

Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia

Sponsors & Collaborators

  • Ageless Regenerative Institute

    lead INDUSTRY

Principal Investigators

  • Sharon McQuillan, MD · Ageless Regenerative Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2017-11-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02087397 on ClinicalTrials.gov